BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10692041)

  • 1. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
    Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro.
    Nishi N; van der Vliet HJ; Koezuka Y; von Blomberg BM; Scheper RJ; Pinedo HM; Giaccone G
    Hum Immunol; 2000 Apr; 61(4):357-65. PubMed ID: 10715513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells.
    Takahashi T; Nieda M; Koezuka Y; Nicol A; Porcelli SA; Ishikawa Y; Tadokoro K; Hirai H; Juji T
    J Immunol; 2000 May; 164(9):4458-64. PubMed ID: 10779745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells.
    Takahashi T; Chiba S; Nieda M; Azuma T; Ishihara S; Shibata Y; Juji T; Hirai H
    J Immunol; 2002 Apr; 168(7):3140-4. PubMed ID: 11907064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.
    van der Vliet HJ ; Nishi N; Koezuka Y; von Blomberg BM ; van den Eertwegh AJ ; Porcelli SA; Pinedo HM; Scheper RJ; Giaccone G
    J Immunol Methods; 2001 Jan; 247(1-2):61-72. PubMed ID: 11150537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.
    Kawano T; Cui J; Koezuka Y; Toura I; Kaneko Y; Sato H; Kondo E; Harada M; Koseki H; Nakayama T; Tanaka Y; Taniguchi M
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5690-3. PubMed ID: 9576945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valpha24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy.
    Takahashi T; Haraguchi K; Chiba S; Yasukawa M; Shibata Y; Hirai H
    Br J Haematol; 2003 Jul; 122(2):231-9. PubMed ID: 12846891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
    Ortaldo JR; Young HA; Winkler-Pickett RT; Bere EW; Murphy WJ; Wiltrout RH
    J Immunol; 2004 Jan; 172(2):943-53. PubMed ID: 14707067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
    Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
    J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
    Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
    Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alpha-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Valpha24+ Vbeta11+ T cells.
    Van Der Vliet HJ; Nishi N; Koezuka Y; Peyrat MA; Von Blomberg BM; Van Den Eertwegh AJ; Pinedo HM; Giaccone G; Scheper RJ
    Immunology; 1999 Dec; 98(4):557-63. PubMed ID: 10594688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
    Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
    Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
    Metelitsa LS; Weinberg KI; Emanuel PD; Seeger RC
    Leukemia; 2003 Jun; 17(6):1068-77. PubMed ID: 12764370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.
    Rogers PR; Matsumoto A; Naidenko O; Kronenberg M; Mikayama T; Kato S
    J Immunol Methods; 2004 Feb; 285(2):197-214. PubMed ID: 14980434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
    Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms.
    Gansuvd B; Hagihara M; Yu Y; Inoue H; Ueda Y; Tsuchiya T; Masui A; Ando K; Nakamura Y; Munkhtuvshin N; Kato S; Thomas JM; Hotta T
    Hum Immunol; 2002 Mar; 63(3):164-75. PubMed ID: 11872234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.